98%
921
2 minutes
20
This study aimed to perform a systematic review and meta-analysis on the hepatoprotective effects of naringin based on the pre-clinical evidence.A detailed literature search was performed using online databases such as Google Scholar, PubMed, Scopus, and EMBASE. Based on the predefined inclusion and exclusion criteria, 20 studies were considered for meta-analysis.The outcomes of the meta-analysis revealed that naringin improved liver function by reducing the elevated levels of ALT, AST, GGT, LDH, ALP, and bilirubin. It improved the enzymatic and non-enzymatic antioxidants, such as SOD, catalase, GSH, GST, GR, and GPx (p < 0.05 for all the parameters), while reducing the LPO/MDA levels (p < 0.05). NAR treatment also alleviated the levels of inflammatory mediators (IL-1, IL-6, and TNF-, p < 0.001 for all the parameters; NF-B, p = 0.29) in various animal models of liver injury. In addition, NAR significantly reduced the caspase-3 and Bax/Bcl-2 ratio (p < 0.05) compared to the control group. Furthermore, naringin treatment has normalised the liver and body weights compared to the disease control group.This systematic review and meta-analysis demonstrate that naringin significantly improved the liver function in various animal models of liver injury, via potent antioxidant and anti-inflammatory mechanisms.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1055/a-2595-7650 | DOI Listing |
Arch Pharm Res
September 2025
Department of Biosciences, JIS University, 81, Nilgunj Road, Agarpara, Kolkata, West Bengal, 700109, India.
Bacoside A (BCA), a triterpenoid saponin isolated from Bacopa monnieri, exhibits diverse pharmacological properties, including neuroprotective, hepatoprotective, anti-stress, anti-inflammatory, and anti-ulcer effects. In the present study, BCA demonstrates pronounced anticancer activity against K562 chronic myelogenous leukemia (CML) cells by modulating autophagy-apoptosis dynamics. BCA induces dose- and time-dependent cytotoxicity in K562 cells while sparing normal human peripheral blood mononuclear cells (hPBMCs) and Vero cells, indicating therapeutic selectivity.
View Article and Find Full Text PDFAnalyst
September 2025
Institute of Basic Theory for Chinese Medicine, China Academy of Chinese Medical Sciences, Beijing, China.
: Postmenopausal conditions can lead to metabolic disorders such as obesity and steatosis. (PT), a prominent traditional Chinese medicine, exerts potential therapeutic effects against hepatic injury. Nevertheless, the extent to which PT ameliorates liver damage resulting from estrogen deficiency, along with the associated mechanisms, remains poorly understood.
View Article and Find Full Text PDFToxicon
September 2025
National R & D Center for Edible Fungus Processing Technology, Henan University, Kaifeng 475004, China. Electronic address:
Excessive use of pesticides frequently contaminates the environment and poses health risks. This study aimed to investigate the potential hepatoprotective effect of curcumin against the toxic effects of emamectin benzoate in rats. Six groups of male Wistar rats were used: control, curcumin (Cur; 200 mg/kg), Emamectin benzoate - low dose (EMB-LD; 5 mg/kg BW), Emamectin benzoate - high dose (EMB-HD; 10 mg/kg BW), Cur plus EMB-LD, and Cur plus EMB-HD, respectively.
View Article and Find Full Text PDFSteroids
September 2025
Department of Physiology, University of Ilorin, Ilorin, Nigeria.
Background: Emerging evidence indicates that metformin-based combination therapy may offer better glycemic control and improved tolerability compared to diabetes monotherapy. Building on this, vitamin D was considered a potential adjunct to metformin for managing type 2 diabetes. Although vitamin D is primarily recognized for its role in calcium regulation, it also appears to influence glucose metabolism and other non-skeletal functions.
View Article and Find Full Text PDFCell Mol Biol (Noisy-le-grand)
September 2025
Associate Professor, School of Pharmacy, Desh Bhagat University, Mandi Gobindgarh-Punjab 147301, India.
Alcoholic fatty liver disease (AFLD) is a leading cause of chronic liver disease worldwide, contributing to significant morbidity and mortality. Despite its growing prevalence, no FDA-approved pharmacological treatments exist, leaving lifestyle modifications as the primary intervention. AFLD pathogenesis involves a complex interplay of lipid accumulation, oxidative stress, insulin resistance, and inflammation, highlighting the need for innovative therapeutic approaches.
View Article and Find Full Text PDF